In August 2023, a Riley Hospital for Children patient became the first child in Indiana to receive teplizumab, a groundbreaking therapy that delays the onset of stage 3 type 1 diabetes by an average of three years. The treatment received Federal Drug Administration approval in November 2022, three years after Indiana University School of Medicine researchers conducted clinical trials and published data that helped lead to the FDA’s decision.
The Wells Center for Pediatric Research has recognized several researchers with awards during their spring 2023 round of funding to support five promising projects focused on emerging therapies and clinical and translational pediatric research.
IU School of Medicine’s Center for Medical Genomics recently acquired the Illumina NovaSeq X Plus—an instrument that exponentially expands the possibilities of how far next-generation sequencing can go.
In a study published in Blood, researchers from Indiana University School of Medicine shed new light on the underlying causes of negative immune responses to factor VIII treatments, providing valuable insights that could lead to more effective and safer hemophilia A treatments in the future.
Seven scientists from IU School of Medicine have been recognized with 2023 Pilot and Feasibility (P&F) Awards from the Center for Diabetes and Metabolic Diseases (CDMD) at Indiana University School of Medicine, an NIDDK-designated Diabetes Research Center.
Cristian Lasagna-Reeves, PhD, received an award at the 2023 Alzheimer’s Association International Conference for the “most impactful study published in Alzheimer’s research.” IU School of Medicine is a powerhouse for Alzheimer's research and resources globally.